Vanda Pharmaceuticals' board is unimpressed with takeover offers from both Cycle Pharma and Future Pak, saying they both “substantially undervalue” the company.
AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) –
The European Commission has approved Sobi’s long-acting factor VIII replacement therapy Altuvoct for the treatment of haemophilia A in the EU, with a broad label that spans all ages and any
Amazon’s pharmacy division is expanding its $5-per-month subscription service for generic medicines, making it available for patients enrolled in Medicare.
KalVista Pharma has filed its first marketing application to the US FDA, seeking approval for its oral plasma kallikrein inhibitor sebetralstat as an oral treatment for hereditary angioedem